NCT06966024RecruitingPhase 1
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 2 May 2025
- Start date
- 27 Aug 2025
- Primary completion date
- Feb 2029
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Diseases
- Prostate cancer, Kidney cancer, Bladder cancer
- NCT number
- NCT06966024
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 60
- From 27 Aug 2025 to the primary completion date, Feb 2029
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
- Major surgery within 28 days of the first dose of study drug
Other illness
- Impaired cardiac function
Who the study is looking for
- Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
- Able to take oral medication
- If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
- Adequate organ function and electrolytes
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Recruiting |
| NEXT Oncology - Austin Coordinator of this site? Confirm its status | Austin | United States | Recruiting |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| Vanderbilt-Ingram Cancer Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| Fox Chase Cancer Center Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| NEXT Oncology San Antonio Coordinator of this site? Confirm its status | San Antonio | United States | Recruiting |
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.